GenMont Biotech Incorporation Past Earnings Performance
Past criteria checks 4/6
GenMont Biotech Incorporation's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 0.9% per year. GenMont Biotech Incorporation's return on equity is 2.9%, and it has net margins of 14.4%.
Key information
-2.6%
Earnings growth rate
-2.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 0.9% |
| Return on equity | 2.9% |
| Net Margin | 14.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings
Mar 19
Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)
Apr 04GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.
Feb 14
Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 24Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield
Jan 03Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Revenue & Expenses Breakdown
How GenMont Biotech Incorporation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 369 | 53 | 151 | 47 |
| 30 Jun 24 | 361 | 71 | 154 | 47 |
| 31 Mar 24 | 355 | 59 | 154 | 47 |
| 31 Dec 23 | 318 | 33 | 157 | 47 |
| 30 Sep 23 | 350 | 49 | 163 | 46 |
| 30 Jun 23 | 350 | 33 | 151 | 54 |
| 31 Mar 23 | 357 | 42 | 142 | 65 |
| 31 Dec 22 | 369 | 57 | 135 | 59 |
| 30 Sep 22 | 382 | 87 | 135 | 55 |
| 30 Jun 22 | 411 | 103 | 144 | 41 |
| 31 Mar 22 | 415 | 106 | 154 | 25 |
| 31 Dec 21 | 428 | 113 | 149 | 26 |
| 30 Sep 21 | 395 | 77 | 145 | 25 |
| 30 Jun 21 | 369 | 82 | 131 | 26 |
| 31 Mar 21 | 348 | 83 | 119 | 26 |
| 31 Dec 20 | 325 | 61 | 118 | 26 |
| 30 Sep 20 | 318 | 49 | 110 | 28 |
| 30 Jun 20 | 328 | 36 | 115 | 28 |
| 31 Mar 20 | 336 | 25 | 124 | 28 |
| 31 Dec 19 | 346 | 57 | 125 | 27 |
| 30 Sep 19 | 361 | 86 | 123 | 27 |
| 30 Jun 19 | 390 | 106 | 122 | 27 |
| 31 Mar 19 | 402 | 113 | 126 | 28 |
| 31 Dec 18 | 407 | 98 | 128 | 28 |
| 30 Sep 18 | 385 | 81 | 132 | 28 |
| 30 Jun 18 | 377 | 85 | 135 | 29 |
| 31 Mar 18 | 380 | 136 | 129 | 30 |
| 31 Dec 17 | 381 | 129 | 126 | 29 |
| 30 Sep 17 | 428 | -95 | 164 | 30 |
| 30 Jun 17 | 464 | -145 | 208 | 29 |
| 31 Mar 17 | 508 | -208 | 253 | 28 |
| 31 Dec 16 | 541 | -236 | 299 | 29 |
| 30 Sep 16 | 545 | -76 | 299 | 26 |
| 30 Jun 16 | 562 | -55 | 299 | 26 |
| 31 Mar 16 | 543 | -80 | 294 | 26 |
| 31 Dec 15 | 535 | -98 | 293 | 27 |
| 30 Sep 15 | 516 | -346 | 335 | 28 |
| 30 Jun 15 | 529 | -406 | 357 | 28 |
| 31 Mar 15 | 566 | -405 | 377 | 27 |
| 31 Dec 14 | 565 | -386 | 369 | 29 |
| 30 Sep 14 | 528 | -109 | 300 | 29 |
| 30 Jun 14 | 424 | -45 | 227 | 29 |
| 31 Mar 14 | 352 | 2 | 167 | 30 |
| 31 Dec 13 | 309 | 31 | 130 | 27 |
Quality Earnings: 3164 has high quality earnings.
Growing Profit Margin: 3164's current net profit margins (14.4%) are higher than last year (14%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3164 has become profitable over the past 5 years, growing earnings by -2.6% per year.
Accelerating Growth: 3164's earnings growth over the past year (8.8%) exceeds its 5-year average (-2.6% per year).
Earnings vs Industry: 3164 earnings growth over the past year (8.8%) did not outperform the Biotechs industry 8.8%.
Return on Equity
High ROE: 3164's Return on Equity (2.9%) is considered low.